Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

452.00 +6.80 (+1.53%)
Streaming Delayed Price Updated: 2:50 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for Decades
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades'
CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation. 
Via Benzinga
Topics Artificial Intelligence
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.
Via The Motley Fool
Topics Economy Government World Trade
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Government
Is Vertex Pharmaceuticals Stock a Buy?
Via The Motley Fool
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?
A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited. 
Via Benzinga
Topics Stocks World Trade
Vertex to Announce First Quarter 2025 Financial Results on May 5th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy. 
Via Benzinga
2 Stocks to Buy if You're Worried About a Recession
Via The Motley Fool
Topics Economy Government
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm
Via The Motley Fool
Topics Earnings Economy Government
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
Via The Motley Fool
Topics Economy Energy Government
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen... 
Via StockStory
Topics Artificial Intelligence
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy. 
Via Stocktwits
Topics ETFs Government
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
Via Benzinga
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval. 
Via Benzinga
Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout. 
Via Chartmill
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
Via Benzinga
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession
Via The Motley Fool
Topics Economy Government Stocks
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.